
    
      To determine levels of glycosaminoglycans (GAGs), including dermatan sulfate (DS) and heparan
      sulfate (HS), GAG-degradation products, and other biomarkers of central nervous system (CNS)
      and lysosomal function in cerebrospinal fluid (CSF) in pediatric and adult patients with
      Hunter syndrome.
    
  